Login / Signup

Addition of bioimpedance-derived body cell mass improves performance of serum creatinine-based GFR estimation in a chronic kidney disease cohort.

Ranjit SinghMajibullah AnsariS Namrata RaoAbhilash ChandraShashwat VermaPrabhaker MishraAyush Lohiya
Published in: International urology and nephrology (2023)
Clinical Trials Registry of India (CTRI/2019/11/021850).
Keyphrases
  • chronic kidney disease
  • clinical trial
  • end stage renal disease
  • single cell
  • body composition
  • cell therapy
  • stem cells
  • metabolic syndrome
  • bone marrow
  • study protocol